DWA
SYRE icon

Delos Wealth Advisors’s Spyre Therapeutics SYRE Stock Holding History

Delos Wealth Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-250
Closed -$12.6K – 343
2026
Q1 		$12.6K Buy
+250
New +$9.43K 0.01% 171

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Delos Wealth Advisors's SYRE Position: Q2 2026 in Review

Delos Wealth Advisors sold out of Spyre Therapeutics (SYRE) in Q2 2026, closing a stake of 250 shares — an estimated $12.6K sold.

Delos Wealth Advisors first reported a position in SYRE in Q1 2026 and held it in 1 quarter. The position peaked at $12.6K in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Delos Wealth Advisors reported no remaining Spyre Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Delos Wealth Advisors sold 250 Spyre Therapeutics shares in Q2 2026, an estimated $12.6K.
  • Delos Wealth Advisors first reported a position in Spyre Therapeutics in Q1 2026 and held it in 1 quarter.
  • Delos Wealth Advisors's Spyre Therapeutics position peaked at $12.6K in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Delos Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.